Skip to Main Content
scipher medicine
  • Company
  • Solutions
  • Resources
  • Contact Us
A network medicine approach to discover common novel drug target mechanisms across autoimmune diseases

A network medicine approach to discover common novel drug target mechanisms across autoimmune diseases

Oct 1, 2021

Ghiassian, Susan PhD; Withers, Johanna PhD; Akmaev, Viatcheslav PhD The American Journal of Gastroenterology: October 2021 – Volume 116 – Issue – p S431-S432 Abstract: Introduction: The map of human disease biology called the human interactome (HI)...
A molecular signature response classifier stratifies seropositive rheumatoid arthritis patients based on their likelihood of inadequate response to TNF inhibitor therapies

A molecular signature response classifier stratifies seropositive rheumatoid arthritis patients based on their likelihood of inadequate response to TNF inhibitor therapies

Sep 8, 2021

Cohen S, Wells AF, Curtis JR, Dhar R, Mellors T, Zhang L, Withers JB, Jones A, Ghiassian SD, Wang M, Connolly-Strong E, Rapisardo S, Gatalica Z, Pappas DA, Kremer JM, Saleh A, Akmaev VR. Rheumatol Ther. 2021 Sep;8(3):1159-1176.  Abstract: Introduction: Timely matching...
A high-confidence definition of therapeutic response in rheumatoid arthritiss using a Monte Carlo simulation approach

A high-confidence definition of therapeutic response in rheumatoid arthritiss using a Monte Carlo simulation approach

Jun 10, 2021

V. Strand, S. Cohen, L. Zhang, T. Mellors, A. Jones, J. Withers, V. Akmaev Annals of the Rheumatic Diseases 2021;80:1097-1098. Abstract: Background: Therapy choice and therapy change depend on the ability to accurately assess patients’ disease activity. The clinical...
A molecular signature response classifier predicts the likelihood of eular nonresponse to TNF inhibitor therapies in RA: results from a retrospective cohort analysis

A molecular signature response classifier predicts the likelihood of eular nonresponse to TNF inhibitor therapies in RA: results from a retrospective cohort analysis

Jun 10, 2021

L. Zhang1 , C. van der Tog2 , A. den Broeder2 , T. Mellors1 , E. Connolly-Strong1 , J. Withers1 , A. Jones1 , V. Akmaev1 . 1 Scipher Medicine Corporation, Science and Technology, Waltham, United States of America; 2 Sint Maartenskliniek, Department of Rheumatology,...
Network medicine framework for identifying drug-repurposing opportunities for COVID-19

Network medicine framework for identifying drug-repurposing opportunities for COVID-19

Mar 30, 2021

Deisy Morselli Gysi, Ítalo do Valle, Marinka Zitnik, Asher Ameli, Xiao Gana, Onur Varola, Susan Dina Ghiassian, J. J. Patten, Robert A. Davey, Joseph Loscalzo, and Albert-László Barabási Proceedings of the National Academy of Sciences Abstract: Introduction: The...
A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study

A systems-based method to repurpose marketed therapeutics for antiviral use: a SARS-CoV-2 case study

Feb 16, 2021

Mengran Wang, Johanna B Withers, Piero Ricchiuto, Ivan Voitalov, Michael McAnally, Helia N Sanchez, Alif Saleh, Viatcheslav R Akmaev, Susan Dina Ghiassian Abstract: Introduction: Viruses are obligate intracellular parasites that can only replicate by entering into a...
« Older Entries
Next Entries »
Scipher Medicine Logo

Company

  • About Us
  • Team/Advisors
  • Careers

Solutions

  • Diagnostics
  • Data Lake
  • Therapeutics
  • Market Access

Resources

  • News/Events
  • Press
  • Publications
  • Media Kit
Contact Us

info@sciphermedicine.com

Privacy Policy / Patient Opt-out Information / Notice of Privacy Practices / Terms of Use / Cookies Acknowledgement / Notice of Nondiscrimination

© 2024 Scipher Medicine. All rights reserved. Privacy Policy